Whether Trelagliptin can cure diabetes and the actual effect of long-term treatment

Trelagliptin is a long-acting dipeptidyl peptidase -4 (DPP-4) inhibitor, mainly used to treat type 2 diabetes. It inhibits the activity of DPP-4enzyme, prolongs the action time of glucagon-like peptide-1 (GLP-1), promotes the secretion of insulin by pancreatic β cells and inhibits the secretion of glucagon by α cells, thereby reducing postprandial blood sugar levels. This mechanism improves glycemic control but does not cure diabetes because it cannot reverse the loss of pancreatic beta cell function or completely eliminate metabolic abnormalities.

Clinical studies have shown that trotagliptin can significantly reduceHbA1c levels and improve fasting blood glucose and postprandial blood glucose under single or combined treatment. The convenience of one-time or weekly dosing improves patient compliance and reduces blood sugar fluctuations. Significant blood glucose improvement can usually be observed within 12 weeks to 24 weeks of short-term treatment, but the sustainability of the effect still depends on the patient's lifestyle, dietary control and other treatment options.

Studies on long-term use of trolagliptin (eg, more than one year) show that it has stable blood sugar control and high safety. Compared with other antidiabetic drugs, trotagliptin is less likely to cause hypoglycemia, results in neutral or slight weight loss, and is well tolerated. However, since diabetes is a chronic and progressive disease, long-term efficacy still requires a combination of diet, exercise, life management and combined medication. Trolagliptin itself cannot reverse the loss of pancreatic isletβ cell function, nor can it completely prevent the occurrence of complications.

In clinical practice, trotagliptin is suitable for patients with early or mid-stage 2 type 2 diabetes. It can be used as a single drug or in combination with metformin, insulin, etc. to optimize blood sugar control. Patients should maintain regular review of HbA1c and blood sugar levels, combined with lifestyle intervention, to achieve the best treatment effect. At the same time, it is necessary to clarify its positioning of controlling blood sugar rather than curing diseases, so as to reasonably predict the efficacy and improve long-term management compliance.

Reference materials:https://www.drugs.com/